Strategic Investments and Adjusted Gross Margin Report
PRODUCT DEVELOPMENT COLLABORATION
Organigram and BAT contributing complimentary capabilities and sharing a commitment to responsible
category stewardship. The PDC continues to focus on the development of next generation products,
adhering to the highest regulatory and compliance standards
Collaboration Highlights
•
•
Since March 2021, following a C$221 million strategic investment from BAT subsidiary,
the partnership has gone from strength-to-strength
Significant achievements have materialized from a scientific development standpoint
in terms of revenue driving product capability
Organigram has benefitted from BAT's deep understanding of plant science and
device and product technology
BAT has gained substantial knowledge from Organigram with respect to the cannabis
plant and product category
The PDC is in late-stage development of a suite of emulsions, novel vapour
formulations, flavour innovations, and packaging solutions which are to be applied
across some products in Organigram's portfolio in calendar year 2024
For ingestible innovations, Organigram has completed pharmacokinetic (PK)
studies to substantiate benefits of emulsification technologies and analysis of
results is underway
BAT
A BETTER TOMORROW
"PDC"
ORGANIGRAM
Dedication to Research and Product Development
ORGANIGRAM
10View entire presentation